Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy

Bibliographic Details
Main Authors:	Zuyu Liang, Jiazhen Cui, Alex Hongsheng Chang, Jian Yu, Yongxian Hu, He Huang
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Regenerative Therapy
Subjects:	Acute lymphoblastic leukemia Bispecific chimeric antigen receptor T cells CD20/CD22 CD19
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352320420300845

Similar Items

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
by: Hanren Dai, et al.
Published: (2020-04-01)

Targeting CD22 for the Treatment of B-Cell Malignancies
by: Shah NN, et al.
Published: (2021-07-01)

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
by: Hua J, et al.
Published: (2020-03-01)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
by: Ying Zhang, et al.
Published: (2021-05-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
by: Guoqing Wei, et al.
Published: (2017-04-01)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
by: Yao Sun, et al.
Published: (2021-10-01)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
by: Zhu H, et al.
Published: (2021-07-01)

Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
by: Frank Breitling, et al.
Published: (2013-05-01)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
by: Sakthi Rajendran, et al.
Published: (2019-09-01)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
by: Christian Kellner, et al.
Published: (2018-08-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

Oil Red O positive vacuolated blasts in a case of CD45 negative, CD19 negative B-lymphoblastic leukemia
by: Diana O. Treaba, MD, et al.
Published: (2016-12-01)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
by: Robert J. Cronk, et al.
Published: (2020-09-01)

CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
by: Bingyu Li, et al.
Published: (2018-01-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Blinatumomab bridges the gap between leukemia and immunity
by: Takahiro Yamazaki, et al.
Published: (2017-11-01)

A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines
by: Xiaoyun Liu, et al.
Published: (2011-04-01)

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
by: Francesco Lanza, et al.
Published: (2020-01-01)

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
by: Zhaoyi Li, et al.
Published: (2019-01-01)

Petanda Imunofenotip CD10 Sendiri Atau Bersama CD3 Atau CD13/CD33 sebagai Faktor Prognosis Luaran Terapi Fase Induksi Leukemia Limfoblastik Akut Anak
by: Eggi Arguni, et al.
Published: (2018-04-01)

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
by: Xiaolong Zhang, et al.
Published: (2017-02-01)

A T-acute lymphoblastic leukemia in children with CD 117 expression: a case report
by: Komang Juwita Endrawati, et al.
Published: (2019-08-01)

A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
by: Yuexian Zhou, et al.
Published: (2020-05-01)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
by: Atsushi Kuwahara, et al.
Published: (2020-11-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2018-01-01)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
by: William R. Strohl, et al.
Published: (2019-07-01)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
by: Joseph Kauer, et al.
Published: (2021-09-01)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
by: Andres Lopez-Albaitero, et al.
Published: (2017-03-01)

Impact of CD105 Flow-Cytometric Expression on Childhood B-Acute Lymphoblastic Leukemia
by: Elkholy RA, et al.
Published: (2021-03-01)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
by: Delong Liu, et al.
Published: (2019-02-01)

Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis
by: Xinjie Xu, et al.
Published: (2021-04-01)

CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
by: Peter E. van Bommel, et al.
Published: (2018-02-01)

Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis
by: Komal Adeel, et al.
Published: (2021-01-01)

CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
by: Fatih M. Uckun, et al.
Published: (2021-09-01)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
by: Hejin Jia, et al.
Published: (2019-06-01)

Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia
by: Anna Płoszyńska, et al.
Published: (2012-07-01)

Cannot write session to /tmp/vufind_sessions/sess_0sua3sd7vjvqk6saropfed3t1m